Donor T cell activity

Donor T cell activity refers to the immunological functions mediated by T lymphocytes originating from a donor after transplantation (usually hematopoietic stem cell transplantation). Donor T cells are central to both beneficial and deleterious outcomes: they mediate the graft-versus-host effect—attacking the recipient's tissues, leading to GVHD—and contribute to defense against infections and recurrence of malignancies (graft-versus-leukemia effect). T cell depletion from the donor graft can prevent GVHD but may compromise anti-tumor and anti-infective defense. Drugs that modulate this activity primarily act by suppressing T cell activation, depleting T cells, or altering T cell signaling pathways. While tracking and controlling donor T cell activity is critical for transplant outcomes, the term is not a single molecular therapeutic target but a descriptive term for the activity/state of transferred immune cells. "Donor T cell activity" refers to the functional activity of a population of donor-derived immune cells, not a specific molecule or classical therapeutic target. It is thus not appropriate as a primary entry for molecular drug target databases, but is critical to outcomes in transplantation medicine.

Other names

Donor T cellsDonor-derived T lymphocytesAlloreactive T cells (in context of transplantation)Donor-reactive T cells

These refer to general methods by which therapies reduce or modulate donor T cell activity: Depletion of T cells (serotherapy with ATG or alemtuzumab); Inhibition of T cell activation (calcineurin inhibitors, CTLA4-Ig); Suppression of cytokine production (steroids, calcineurin inhibitors); Modulation of costimulatory signaling (abatacept, anti-CD28); Expansion of regulatory T cells to induce tolerance.